Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation

Filing is planned for late 2004/early 2005 based on positive Phase III results. I.V. infusion formulation of ibandronate would be the first injectable bisphosphonate for osteoporosis, administered once every two or three months.